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Summary Identification and quantitative evaluation of drug resistance markers are essential to assess the impact of multidrug resistance
(MDR) in clinical oncology. The MDR1 gene confers pleiotropic drug resistance in tumour cells, but other molecular mechanisms are also
involved in drug resistance. In particular, the clinical pattern of expression of the other MDR-related genes is unclear and their inter-
relationships are still unknown. Here, we report standardization of the procedures used to determine a reliable method of semiquantitative
reverse transcriptase polymerase chain reaction (RT-PCR) using a standard series of drug-sensitive and increasingly resistant cell lines to
evaluate the expression ofthree MDR-related genes, i.e. MDR1 (multidrug resistance gene 1), MRP(multidrug resistance related protein) and
GSTp (glutathione-S-transferase p), reported to be endogenous standard genes for normalization of mRNAs. A total of 74 breast cancer
surgical biopsies, obtained before any treatment, were evaluated by this method. When compared with classical clinical and laboratory
findings, GSTp mRNA level was higher in diploid tumours. However, the main finding of our study suggests a clear relationship between two
of these MDR-related gene expressions, namely GSTp and MRP. This finding provides new insight into human breast tumours, which may
possibly be linked to the glutathione conjugate carrier function of MRP. Well defined semiquantitative RT-PCR procedures can therefore
constitute a powerful tool to investigate MDR phenotype at mRNA levels of different related genes in small and precious tumour biopsy
specimens.
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A wide variety of cell changes, either spontaneous or induced by
cytotoxic exposure, can lead to multidrug resistance phenotype
(MDR) (Simon and Schindler,1994). They are frequently inter-
related and may coexist in a population of tumour cells. Some
proteins have been demonstrated to be overexpressed in MDR cell
lines, defining a group of MDR-related genes. The first of these
proteins to be identified was P-glycoprotein (P-gp), product ofthe
MDRJ (multidrug resistance gene 1) (Endicott and Ling, 1989;
Gottesman and Pastan, 1993) gene in man, belonging to the
ATP-binding cassette (ABC) proteins superfamily, all members of
which are membrane transporters. The multidrug resistance
related protein (MRP), which has been recently demonstrated to be
involved in the MDR phenotype (Cole et al, 1992; Slovak et al,
1993), is a 190 kDa protein, which also belongs to the ABC trans-
porter superfamily. Like P-gp, MRP, which is mainly located in the
plasma membrane ofresistant cells (Flens et al, 1994; Zaman et al,
1994; Almquist et al, 1995) acts by extruding drugs from the cells
(Breuninger et al, 1995). Among other proteins frequently over-
expressed in tumour cells presenting a MDR phenotype, GSTp
(glutathione-S-transferase p) has been extensively implicated
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(Moscow et al, 1989; Tew, 1994), although its precise role in the
MDR phenomenon has not yet been fully clarified.
The development of drug resistance marker evaluation in clin-
ical samples is therefore particularly worthwhile to lead subse-
quently to prospective clinical correlative studies. Transcriptional
rate measurement ofthe genes involved in MDR constitutes a first
step to delineate the in vivo mechanisms used by tumour cells to
acquire clinical MDR characteristics. To date, partly due to high
material consuming methods, the majority of investigations in
patients have focused on a single parameter, mainly P-gp expres-
sion. Multiparameter studies, which are not always easily
performed on small tissue samples, can use low material
consuming methods such as reverse transcriptase polymerase
chain reaction (RT-PCR) or RNAase protection assay to
simultaneously screen the transcriptional rate of sets of genes
involved in MDR.
The main goal of the present study was, therefore, to develop a
technically valid method able to investigate the coexpression of
three MDR-related genes, i.e. MDRJ, MRP, and GSTp on small
tumour specimens. The first step in this process, using RT-PCR,
was to establish standard curves to semiquantitatively measure the
expression ofdrug resistance genes in control cell lines. They were
independently ascertained and their respective precise experi-
mental procedures are reported here.
In the second part of this study, we used this method to screen
the MDR phenotype of a consecutive series of 74 untreated inva-
sive breast carcinomas and to compare the levels ofexpression of
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each of the three genes with the other two drug resistance genes.
The MDR phenotype appeared independent of other clinical,
histopathological and laboratory parameters, except that diploid
tumours exhibited a higher level of GSTp expression than aneu-
ploid tumours. However, our study provides a new intriguing clue
in the clinical investigation of MDR, by demonstrating, for the
first time in human tumour samples, a clear relationship between
MRP and GSTp gene expression. This finding needs to be
discussed in the light of the considerable recent experimental
evidence (Jedlitschky et al, 1994; Muller et al, 1994; Zaman et al,
1995) concerning the role ofthe membrane associated MRP pump
in the export ofglutathione S conjugates (GS-X) from cells.
MATERIALS AND METHODS
Patients and tissue samples
Seventy-four tumour samples were obtained during surgery from
previously untreated primary breast cancers. All patients gave
their informed consent before surgery. Samples (100 mg to 1 g)
were removed from the tumour zone, immediately snap frozen and
stored in liquid nitrogen, then cut into several equal pieces for the
various analyses. Representative samples were examined histolog-
ically to ensure very large predominance of tumour over stromal
cells (above 90%) in samples used for analysis. Histopathological
typing, Scarff-Bloom-Richardson (SBR) grading and measure-
ments of oestrogen (ER) and progesterone (PR) receptor levels
(cut-off values 10 fmol mg-' protein) were performed by other
independent investigators (Pathology Department - hopital Pitie-
Salpetriere, Professor Lecharpentier and Biochemistry Laboratory
- h6pital Bicetre, Professor Milgrom) in a tumour area very close
to the surgical specimen.
Flow cytometry procedures
Flow cytometry was performed afterDNA labelling with propidium
iodide (SigmaChemical, StLouis, MO,USA). A single-cell suspen-
sion was prepared from each tumour sample by mechanical disag-
gregation, as describedpreviously (Coste etal, 1996). CellularDNA
content was analysed on an Epics Elite flow cytometer (Coulter
Electronics, Hialeah, FL, USA). Debris and clumps were eliminated
and the results were recorded on 15 000 cells.
Table I Designation of RT-PCR primers used for amplification of both MDR-
related genes and internal standards
Transcript Primer sequence (5'-3') Fragment length
MDR1 CCCATCATTGCAATAGCAGG 167
GTTCAAACTTCTGCTCCTGA
P2m ACCCCCACTGAAAAAGATGA 120
ATCTTCAAACCTCCATGATG
MRP GGACCTGGACTTCGTTCTCA 291
CGTCCAGACTTCTTCATCCG
GSTI CTCCGCTGCAAATACATCTC 137
ACAATGAAGGTCTTGCCTCC
PGK CAGTTTGGAGCTCCTGGAAG 247
TGCAAATCCAGGGTGCAGTG
Control tumour cell lines
The drug-sensitive human epidermoid carcinoma KB 3.1 cell line
and its multidrug-resistant derivative KB 8.5 cell line were kindly
donated by M Gottesman (Akiyama et al, 1985). MCF7 human
breast carcinoma cells (Soule et al, 1973) were obtained from J
Robert, who selected a doxorubicin-resistant cell line (MCF7R)
from MCF7S wild-type cells. The IGROV cell line was a gift from
J Benard (1985).
Cell culture media and their supplements were obtained from
Gibco BRL (Eragny, France). The KB cell lines were maintained
in Dulbecco's modified Eagle medium, while MCF7 and IGROV
cell lines were grown in RPMI 1640 medium. All were supple-
mented with 1.5 mm glutamine, 10% fetal calf serum, 50 IU ml
penicillin and 50 mg ml-' streptomycin. Cells were cultured at
37°C in a humidified atmosphere containing 5% carbon dioxide.
The selection pressure was maintained on resistant cell lines by the
addition ofeither 10 ng ml ofcolchicine or 2 mm doxorubicin for
KB 8.5 and MCF7R respectively.
Semiquantitative RT-PCR analysis
Semiquantitative determination of MDRJ, GSTp and MRP gene
expression was assessed on a single tissue sample per patient. As
proposed by Noonan et al (1990) and as more recently recom-
mended (Beck et al, 1996), we used the ,B2-microglobulin (p2)
gene as the internal control sequence for MDR] analysis. As the
MCF7R cell line did not express 32, MRP and GSTp gene expres-
sion was monitored using the phosphoglycerate kinase (PGK) gene
as endogenous standard (Ozcelik et al, 1995).
Total RNA was extracted from either control cell lines or tissue
samples using RNA BTM protocol (Bioprobe Systems, Montreuil,
France), according to the manufacturer's instructions. RNAs were
quantitated by absorbance spectrophotometry measurements and
their quality was estimated after migration on a 2% agarose gel.
A 2-jg sample of total cellular RNA from each adequate RNA
preparation was treated in a 10-pl volume, with 2 units ofDNAase
I from bovine pancreas (BoehringerMannheim) in the presence of
20 units of RNAase inhibitor (Boehringer Mannheim) for 15 min
at 37°C. DNAase I was inactivated by heating for 5 min at 65°C
before cDNA preparation. cDNA was then synthesized from
DNAase treated RNA in a 20-pl reverse transcription reaction
mixture containing 100 ng of random hexamer primers
(Pharmacia, Sollentuna, Sweden), 4 pl of buffer 5X, 2 pl of0.1 M
dithiothreitol (Gibco), 2 gl of dNTPs 5 mm (Boehringer), and
100 U of reverse transcriptase Superscript II (Gibco, UK). After
15 min at 42°C, cDNA was diluted to 1:5 with water then stored at
- 20°C until use.
PCR amplification was performed on 5 p1 of the RT product
incubated with 1 U of Taq polymerase (ATGC, Noisy le grand,
France) in a 25-gl reaction mixture containing 0.5 mM deoxy-
nucleoside triphosphate, 2.5 mm magnesium chloride, 2.5 pl of
10 x Taq polymerase buffer from ATGC, 10 pmol ofboth specitic
and internal standard gene upstream and downstream primers to
minimize tube-to-tube variations in amplification efficiency, and
1 jCi of [a-32P]dCTP (Amersham, Les Ulis, France), which
was always used within 5 days of the date of radiolabelling indi-
catedby the manufacturer. The amplimer sequences forMDR] and
P2 (Noonan et al, 1990), PGK (Ozcelik et al, 1995), MRP
(Abbaszadegan et al, 1994) and GSTp (Morrow et al, 1989) are
those previously published (Table 1).
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Table 2 Characteristics of patients and samples
Characteristics n %
Age (years)
< 50 23 31
.50 51 69
Tumour size (mm)
<30 57 77
.30 17 23
Axillary nodal status
N- 65 88
N+ 9 12
Histological typing
Infiltrating ductal carcinomas 63 85
Infiltrating lobular carcinomas 10 13
Others 1 2
Histological grading (SBR)
19 26
11 42 59
III 11 15
Oestrogen receptor status
Negative 14 28
Positive 35 72
Progesterone receptor status
Negative 16 33
Positive 33 67
*SBR, Scarff-Bloom and Richardson index. The cut-off value is 10 fmol mg-'
protein for both oestrogen and progesterone receptors.
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PCR was carried out in a thermal cycler (Perkin Elmer, Paris,
France), and, after an initial denaturation at 95°C for 5 min, PCR
consisted of 30 cycles, corresponding to the exponential range of
the amplification reaction. The thermal profile was as follows: 60 s
at 940C, 60 s at 550C and 90 s at 72°C. Negative control reactions,
containing water instead of cDNA, were included in each experi-
ment. Three microlitres of the radiolabelled PCR products were
submitted to run on 8% polyacrylamide gel electrophoresis in a
buffer containing 89 mm Tris-borate and 2 mM ethylenediamine
tetraacetate disodium (EDTA, pH 8.3) at 50 V cm-'. Gels were
dried for 2 h at 80°C then exposed against X-O-Mat films
(Eastman Kodak) for 6 h at - 800C. Autoradiographs were
densitometrically scanned on a Biorad densitometer (Biorad, Ivry,
France) using Molecular Analyst software (Biorad). Specific gene
expression was determined semiquantitatively by calculating the
ratio of the densitometric values from specific genes expressed in
relation to the intemal standard.
Determination of standard curves
For each gene investigated, a semiquantitative determination
method of RT-PCR yields was developed using a standard curve
established from three RT-PCR reactions from control cell lines
assessed under identical reaction conditions. MDR] gene expres-
sion was determined by densitometry estimating the MDR1432
ratio from autoradiographs obtained following coamplification of
MDRJ and [2 cDNA from serial dilutions ofdrug-resistant KB 8-5
cells with drug-sensitive KB 3-1 cells.
C
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Figure 1 Semiquantitative RT-PCR determination of MDR1, MRPand GSTp gene expression in control cell lines. Standard curves (bottom) were established
for MDR1 (A), MRP(B) and GSTp (C) using serial dilution standard series of drug sensitive (KB 3.1, IGROV and MCF7S respectively) RNA and increasingly
resistant cell line (KB 8.5 for MDR1 and MCF7R for both MRPand GSTp) total RNA. Autoradiograms (top) of RT-PCR products (30 cycles) from MDR related
genes and internal standards were densitometrically scanned for calculation of respective MDR-related gene/internal standard ratios. Inserts show the ranges of
dilution for which amplification ratio and MDR-related gene mRNA showed a linear increment and were strictly proportional. The parametric Pearson correlation
was used for data analysis
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MRP/PGK and GSTp/PGK standard curves were established by
serial dilutions of MCF7R cells with either IGROV or MCF7S
cells respectively.
The values of these ratios were independently assessed for
respective control cell lines on six experiments performed under
identical reaction conditions and the coefficient of variation was
calculated for each one.
Statistical analysis
Linear regression was used to model standard curves (with
Pearson coefficient of correlation). Spearman rank order correla-
tion analysis was performed to test all other continuous variables,
namely correlation studies between the expression of the three
genes. Mann-Whitney non-parametric tests were performed to
compare continuous clinicopathological and laboratory variables.
A nominal significance level of a' = 0.01 was used for individual
tests to guarantee an overall level of a = 0.05 with ten stages.
RESULTS
Sample characteristics and flow cytometry
Table 2 summarizes the main characteristics of the samples: 23
(31%) patients were under 50 years of age, ranging from 21 to 49
years, and 51 (69%) were over 50 years old, ranging from 50 to 84
years with a mean of 42.2 ± 6.1 and 60.2 ± 8.2 respectively. The
majority of the tumours were locally non advanced, as 57 (77%)
were less than 3 cm in diameter (15.4 ± 6.1 mm) and 65 (88%)
were node negative. All tumours were non-metastatic. All were
invasive tumours: 63 (85%) were ductal cancers whereas ten
(13%) were oflobular origin; only one was ofmedullary type and
was not taken into account in the subsequent statistical analysis.
The hormonal status was available on 49 samples for tissue
receptor determination: 35 (72%) were classified as oestrogen
receptor (ER)-positive, whereas 33 (67%) were considered to be
progesterone receptor (PR)-positive.
Sixty four samples were evaluated for flow cytometry studies.
Tumours containing a single cell population with a DNA index
ranging between 0.9 and 1.1 were classified as diploid (n = 34,
55%); those with an additional cell population with a DNA index
beyond the limits of0.9 and 1.1 were defined as aneuploid (n = 28,
45%). None ofthe samples was exclusively composed of a single
cell population with an aneuploid index.
RT-PCR analysis
Determination ofstandard curves
Standard curves for RT-PCR analysis are shown on Figure 1.
The MDRJ standard curve was obtained by submitting serial
dilutions of total RNA from KB 8.5 cells mixed with total RNA
extracted from KB 3.1 cells not expressing the MDRJ gene to RT-
PCR (Figure IA). This curve was used to define a range of dilu-
tions within which the MDRJ/j2 ratio increased in a strictly linear
fashion with the dilution factor. As shown more precisely on the
inset, this range extended from 1/256 to 1/16 (y = 9.4x + 0.03, r =
0.992). This result is consistent with that reported by Chevillard et
al (1996) using the KBAI cell line as MDRJ-positive control.
Under these conditions, with linear increment of the curve, the
MDRJ/f2 ratio increased in proportion to increasing concentra-
tions ofMDRJ mRNA contained in the KB 8.5/KB 3.1 RNA mix
Table 3 RT-PCR determination in control cell lines (arbitrary units)
MDR1/f2 MRP/PGK GST pIPGK
mean ± s.d. mean ± s.d. mean ± s.d.
(CV %) (CV %) (CV %)
KB3.1 0 - -
(0%)
KB 8.5 0.836 -
± 0.064
(8%)
MCF7S - - 0
(0%)
MCF7R - 1.140 0.784
± 0.051 ± 0.055
(4.5%) (7%)
IGROV - 0.243 -
+ 0.018
(7.4%)
The coefficient of variation (CV) was calculated on six independent
experiments.
to
IS4
*1
Is I
S 1%
a
*
*0 . ..
0
2. ,S 1 o.'
.. .a.a.w.
.
* .. V. -; -
i > , ...
Figure 2 RT-PCR analysis of tumour samples. MDR1, MRPand GSTp
mRNA content was expressed in relation to respective internal standards
(,2 for MDR1 and PGKfor both MRPand GSTp). The results are expressed
as the percentage of the ratio assessed in each set of experiment for positive
control cell lines (KB 8.5 and MCR7R for MDR1 and both MRPand GSTp
respectively). Horizontal bars represent the mean values of the series
and there was no competition for PCR between the two couples of
primers. Finally, as reported in Table 3, the coefficient ofvariation
calculated from six determinations of the MDRI/f2 ratio on KB
8.5 assessed under identical reaction conditions was low (8%),
allowing us to compare tumour samples with KB 8.5 cells in
subsequent rounds ofPCR.
To establish the MRP standard curve, total RNA from the MRP-
positive MCF7Rcell line was diluted in RNAextracted from the low
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Table 4 MDR phenotype and characterisics of tumours
Mean ± s.d.
Characteristics
Age (years)a
<50
.50
Tumour size (mm)
<30
.30
Axillary nodal status
N-
N+
Histological typingb
Infiltrating ductal carcinomas
Infiltrating lobular carcinomas
Histological grading SBRc
11
III
Oestrogen receptor status
Negative
Positive
Progesterone receptor status
Negative
Positive
MDR1
19.2 ± 31.3
12.0 ± 18.1
14.08 ± 24.2
13.07 ± 20.5
14.7 ± 24.1
10.9 ± 12.9
14.4 ± 21.9
14.9 ± 30.9
13.9 ± 26.8
13.7 ± 17.8
18.9 ± 31.1
12.5 ± 14.6
11.0 ± 20.1
12.5 ± 13.7
10.9 ± 20.7
MRP
66.1 ± 26.1
57.3 ± 20.3
56.8 ± 20.7
70.1 ± 26.4
59.2 ± 23.1
66.1 ± 17.2
62.4 ± 23.2
47.3 ± 9.8
63.0 ± 23.9
62.2 ± 22.6
67.4 ± 26.4
51.8 ± 19.0
59.3 ± 19.6
55.7 ± 19.3
57.9 ± 19.9
GSTp
85.1 ±7.7
77.34 ± 31.0
77.8 ± 29.8
85.6 ± 43.6
80.5 ± 33.1
74.7 ± 32.8
80.8 ± 33.8
73.9 ± 29.5
79.6 ± 36.4
80.4 ± 29.7
91.3 ± 45.8
74.0 ± 44.8
84.5 ± 30.0
78.0 ± 41.6
83.2 ± 31 .4
aAge of patients; bother histological types were excluded; cSBR, Scarff-Bloom and Richardson index; Values are mean ± s.d. of
mRNA levels ratios of MDR1, MRP, GSTp RT-PCR products expressed as a percentage of control cell lines. Mann-Witney
tests were used for comparison of these variables. No significant statistical difference was observed. For SBR subgroups,
expression of each MDR-related gene was compared between group and 11, and Ill and 11 and Ill.
MRP expressing IGROV cell line and submitted to RT-PCR (Figure
IB). Under these conditions, the MRP/PGKratio increased linearly
for MCF7R/IGROV RNA dilutions ranging between 1/32 and 1/1
(y = 0.85x + 0.26, r = 0.975). This linear increment for low dilutions
can be explained by the relatively low level ofMRP expression by
MCF7R and by the fact that IGROV cells were not totally negative
for MRP expression (Table 3). As for MDRJ determination, these
RT-PCR procedures, designed to determine MRP expression, were
highly reproducible on the MCF7R cell line with a coefficient of
variation of4.5% on six separate experiments (Table 3).
Similarly, to establish the GSTp standard curve, total RNA from
the GSTp-positive MCF7R cell line was diluted in GSTp-negative
MCF7S cells RNA and submitted to RT-PCR (Figure IC). MCF7
was the first cell line described to overexpress GSTp when selected
by doxorubicin and was subsequently used as areference for GSTp
expression (Batist et al,1986; Moscow et al, 1989). High dilutions,
ranging between 1/512 and 1/16, were characterized by a high
slope (y = 4.8x + 0.003, r = 0.977), whereas weak dilutions,
ranging between 1/8 and 1/1, were characterized by a low slope
(y = 0.33x + 0.49, r = 0.98). Nevertheless, it must be emphasized
that, under these conditions, a plateau could never have been
reached. The coefficient of variation for MCF7R was 7% when
calculated on six GSTp/PGKratio determinations (Table 3).
RT-PCR analysis oftumoursamples
Figure 2 shows the determination ofMDR], MRP and GSTp gene
expression in the 74 samples. When compared with negative KB
3.1 and positive KB 8.5 control cell lines, 13 (17.6%) of the
e..
E* "
5_
.0
*.
NW
113~~~~~~.
*13 !0> I~~~~~h iTqfrJ.
..0
S~~~~~~~~~~~~
-,, --.- i- .:
Figure 3 MDR related gene expression and DNA ploidy Tumours were
classified as diploid when the DNA index ranged between 0.9 and 1.1
(n = 34) and aneuploid when the DNA index was outside these values
(n = 28). RT-PCR products of the three MDR-related genes are expressed as
a percentage of control cell lines. The two groups of samples were compared
using the Mann-Whitney non-parametric test; P < 0.01 was considered to be
significant (*) (a nominal significance level of a' = 0.01 was used for individual
test to guarantee an overall level of a = 0.05 with ten stages)
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Figure 4 Correlation studies between MDR1, MRPand GSTp gene expression in breast tumours. Yields of RT-PCR products are expressed as a percentage
of the MDR-related gene/internal standard compared with the positive control cell lines. For MDR1 and MRP(A), MDR1 and GSTp (B) and MRPand GSTp (C)
expression data, Spearman rank order correlation analysis was used; P< 0.05 was considered to be significant
samples definitely did not express the MDRI gene, whereas 61
(82.4%) were found to express MDRJ: 45 (60.8%) of these
samples showed a gene expression less than 20% of that of KB
8.5; 14 (18.9%) showed moderate expression, between 20 and
100%, whereas only two samples (2.7%) showed slightly higher
expression than the control (101% and 104% of KB 8.5 respec-
tively). If we correlate these values, expressed as a percentage of
the positive control cell line, to the standard curve established by
dilutions ofthe RNA control cell lines, 72 samples (97.3%) corre-
sponded to the linearportion ofthe curve (dilution 1/256 to 1/16 of
the KB 8.5 mRNA dilutions). This observation allowed us to
validate our semiquantitative RT-PCR method when applied to
samples expressing a relatively low level ofMDRJ mRNA, such
as breast cancers.
For MRP expression, the values of MRP/PGK ratio ranged
between 21% and 146% (mean ± s.d.: 60 ± 22.4). Again, only
three tumours expressed MRP/PGK ratio at higher levels than the
MCF7R control cell line (102, 117, and 146% of the MCF7R
values respectively). Considering that the standard curve showed a
linear increment for dilutions between 1/32 and 1/1, 70 of the 74
(94.6%) tumours corresponded to this portion of the curve. The
majority of our samples were therefore able to be evaluated for
MRP gene expression using this method.
Finally, concerning GSTp expression, the GSTp/PGK ratio
ranged between 35% and 197% (mean ± s.d.: 79.8 ± 32.9) of the
MCF7R control cell line. Twenty samples (27%) had a higher ratio
than MCF7R. Thedistribution ofthese values onthe standard curve
indicated that 31 of the 74 tumours (41.9 %) corresponded to the
higher slope ofthe curve (dilutions 1/512 to 1/8), whereas 23 of74
(31.1%) corresponded to the second part ofthe curve (lower slope).
Table 4 reports the levels of expression of the three different
genes in relation to the clinical and laboratory findings ofpatients
and samples. As shown, none of the various subgroups expressed
any of the MDR-related genes with a significant statistical differ-
ence. However, as shown on Figure 3, diploid tumours expressed
GSTp at significantly higher levels than aneuploid tumours
(93.6 ± 33.5 vs 70.9 ± 28.7% ofcontrols, P < 0.007). In contrast,
the proliferation state ofthe two types oftumours did not influence
the expression ofthe three genes (data not shown).
Correlation studies between the expression of the three genes
investigated also revealed a potentially important finding. To
compare theMDR] levels to the levels ofthe other two drug resis-
tance genes, we checked that a correlation close to 1:1 was
observed between ,B2 and PGK levels in clinical samples (not
shown). As shown on Figure 4, althoughMDR] and eitherMRP or
GSTp gene expression did not seem to be correlated, our study
revealed a significant positive correlation between MRP and
GSTp expression when using Spearman correlation (rho = 0.47,
P < 0.0015).
DISCUSSION
The development of accurate and reliable tests to identify MDR
determinants in clinical studies is now one of the major goals in
the follow-up of cancer chemotherapy. Only a few of the many
putative molecular mechanisms for clinical chemoresistance can
be semiroutinely investigated. In addition to the P-gp mediated
multidrug phenomenon, which has been extensively investigated
in human pathology (Fojo et al, 1987; Pastan and Gottesman,
1987; Gottesman et al, 1989; Noonan et al, 1990; Weinstein et al,
1990; Areci et al, 1993 and cited in Gottesman and Pastan, 1993),
other mechanisms have been more recently identified; some, such
as MRP-mediated multidrug resistance, have not been well inves-
tigated, whereas others, such as GSTp, have not been clearly iden-
tified as directly involved in MDR and need to be investigated in
conjunction with other factors.
Our study reports reliable experimental RT-PCR procedures that
are able to simultaneously measure mRNA levels of three MDR-
related genes. A variety of methods using either quantitative or
semiquantitative RT-PCR have been used to determine relative
initial target mRNA in samples. However, in all ofthese methods
undefined variations in amplification efficiency complicate the
interpretation of results and, in an attempt to correct for tube-to-
tube variations in amplification efficiency, most investigators use
internal amplification standards, either gene transcript normally
present in the sample, or an exogenous fragment added to the
amplification reaction. In this study, as in many other studies,
particularly concerning human tumour tissue samples (Noonan,
1990; Horikoshi, 1992; Chevillard, 1996), we chose to use
endogenous standards. One-ofthe greatest advantages ofusing the
expression of an endogenous sequence as an internal standard is
that the reference mRNA and target mRNA are usually processed
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together throughout the experiment, i.e. from RNA extraction until
PCR amplification. This tends to minimize differences in RNA
yield between samples, an important advantage, particularly for
analysis of small tissue samples. In addition, if the entire popula-
tion of RNA is converted to cDNA, the overall efficiency of
cDNA synthesis is somewhat normalized. Our assays were also
performed in agreement with the consensus recommendations
recently proposed by the workshop on MDR] evaluation (Beck et
al, 1996): to work on a dominant tumour cell population in the
exponential range of the amplification reaction; to choose optimal
internal standards; to avoid any competition between primer pairs
in multiplex reactions; and finally to establish PCR assays with
negative controls as well as standard series of drug-sensitive and
increasingly resistant cell lines to establish a titration of the
sequences to be amplified and to be sure that the target/standard
PCR products ratio increases linearly with the initial concentration
of the target sequence during the exponential phase of amplifica-
tion of the two sequences. Concerning this last point, the standard
curves determined in the present work for the three genes investi-
gated, demonstrate that the conditions used here are validated for
the relatively low mRNA levels measured in our series of breast
cancer samples.
The choice ofrelevant control cell lines is particularly important
to validate such a method. Both parental and drug-resistant KB
and MCF7 cell lines are well referenced control cell lines to study
MDR] and GSTp gene expression (Gottesman, 1993; Moscow et
al, 1989). The MCF7R cell line expresses MRP at a relatively
lower level than other classical positive control cell lines, such as
H69AR (Cole, 1992) and GLC4 /ADR (Zijlstra et al, 1987; Zaman
et al, 1993). Nevertheless, the use of this cell line as positive
control for MRP in our study on breast cancer can bejustified, as it
is derived from human breast cancer and also because there is
growing evidence that MRP can act as a membranous glutathione
conjugate carrier (see below). We, therefore, preferred to use the
same positive control cell line for both MRP and GSTpi expres-
sion. The IGROV cell line was chosen as low expressing control
cell line because, to our knowledge, few other cell lines have been
shown to express MRP at low levels when using ultrasensitive
detection methods such as RNAase protection assay or RT-PCR
except the parental H69 cell line as reported by Cole et al (1992).
Indeed, like the GLC4 cell line (Nooter et al, 1995), the IGROV
cell line is weakly positive for MRP expression. Furthermore, the
IGROV cell line expressed the PGK internal standard gene at an
identical level to the MCF7R-positive control cell line.
Concerning the choice ofthe internal standards f2 and PGK, ,2
is the gene recommended for calibrating MDR] in the recent
consensus recommendations. However as MCF7R failed to
express the P2 gene, we therefore had to choose another gene
constitutively expressed in breast, namely PGK, to calibrate MRP
and GSTpi expression (Ozcelik et al, 1995).
From a molecular point of view, the mechanisms of MDR are
often opportunistic in their manipulation and modification of
normal pathways of cellular homeostasis. Consequently, it would
be interesting to evaluate whether a particular subgroup of
untreated breast carcinomas could be isolated before
chemotherapy on the basis ofMDR phenotype.
We showed that MDR] expression was relatively weak in the
overall panel of samples and appeared independent of both clini-
copathological and laboratory features. The present study shows
that MDRJ mRNA quantitation can be considered as an indepen-
dent drug resistance marker in untreated breast cancer when
compared with the expression of other main MDR-related genes.
One of the present questions is whether the assessment of mRNA
by RT-PCR of certain drug resistance markers is relevant to clin-
ical end points of treatment when compared with protein. Charpin
et al (1994) evidenced a good correlation between quantitative
immunocytochemical assay for P-gp and PCR analysis of MDRJ
expression in frozen untreated breast carcinomas. Alvarez et al
(1995) described a drug resistance profile when they quantitated
MDRJ expression by RT-PCR in cell lines. Overexpression of
either the MDR] gene or its P-gp product has been frequently
reported in breast cancer and has often been linked to either in
vitro resistance phenomenon or clinical resistance, namely to
anthracyclines (Fojo et al, 1987; Merckel et al, 1989; Salmon et al,
1989; Schneider et al, 1989; Keith et al, 1990; Ro et al, 1990;
Wishart et al, 1990; Sanfilipo et al, 1991; Verelle et al, 1991;
Wallner et al, 1991; Hennequin et al 1993; Chevillard et al, 1996).
In addition, the presence of increased levels of P-gp in several
types of tumours has been correlated with short progression-free
survival and overall survival (van Kalken et al, 1991). Gregorcyk
et al (1996) demonstrated a greater risk of recurrence at 5 years in
P-gp overexpressing untreated breast carcinomas. Finally, P-gp
overexpression has been correlated with c-erbB-2 expression,
which is known to be another poor prognostic marker in breast
carcinomas (Brotherick et al, 1996).
MRP is ubiquitously expressed in normal human tissue (Zaman
et al, 1993; Kruh et al, 1995; Nooter et al, 1995), but few data are
available concerning MRP expression in human cancers. Kruh et
al (1995) detected transcripts in all of nine breast cancer cell lines.
Using a RNAase protection assay, Nooter et al (1995) classified
breast carcinomas as low MRP-expressing tumours. In the present
study, we confirm that almost all samples tested expressed rela-
tively low levels of MRP mRNA. Using the MRP-specific mono-
clonal antibody MRPrl Flens et al (1996), Nooter et al (1997)
recently reported the first study showing a higher MRP expression
in the operable primary tumour of recurrent breast cancers treated
with first-line systemic chemotherapy. The present work provides
additional evidence concerning a possible relationship with GSTpi
in breast carcinoma (see below).
Our results concerning GSTp mRNA levels are in accordance
with those published by Moscow et al (1988). However, as re-
ported by Shea et al (1990) and Peters et al (1993), we did not find
any relationship between GSTp expression and hormone receptor
status. Such a result is at variance with previous reports (Moscow
et al, 1988; Gilbert et al, 1993). In addition, we also showed that
diploid tumours exhibited higher GSTp mRNA levels than aneu-
ploid tumours. Although GSTp has not been unambiguously
directly involved in MDR (Moscow et al, 1988; Tew, 1994 and
cited in Morrow et al, 1993), its value as a prognostic marker has
to be appraised. Indeed, an increased GSTp expression has been
suggested to be predictive of early recurrence and death in node-
negative breast cancer (Gilbert et al, 1993; Silverstini et al, 1997),
particularly when not treated by adjuvant radiotherapy (Silverstini
et al, 1997).
Finally, one of the main findings of our study is the suggested
relationship between MRP and GSTp expression. There is
convincing evidence that the transport of glutathione conjugates
(GS-X) might be mediated by the membranous MRP, GS-X pump
(Muller et al, 1994; Zaman et al, 1995). In addition, it has been
suggested that the MRP/GS-X pump might transport the metabolic
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derivatives of doxorubicin, but not the native drug (Cole et
al,1994). Zaman et al (1995) have provided important evidence
that cellular GSH is a critical factor for the export of doxorubicin
by the MRP/GS-X pump and Ishikawa et al (1995) proposed a
scheme indicating that both MRP/GS-X pump and metabolic
enzyme systems including GST, as well as GSH, could be criti-
cally involved in the mechanisms underlying doxorubicin resis-
tance. The correlation between MRP and GSTp expression
suggests that genes coding for conjugation enzymes of toxic
compounds to GSH, such as GSTp, as well as MRP/GS-X pump
might be co-regulated during the development of breast tumours
before any chemotherapy and could subsequently be involved in
clinical chemoresistance. Resistance to many anti-cancer drugs
has been linked to increased cellular levels of GSH and
glutathione-S-transferases (Tew, 1994) and, although conjugates
of anthracyclines and vinca alkaloids with GSH have not been
described, this finding is in favour of older experiments in which
resistance to anthracyclines was found to be correlated with
increased levels of cellular GSH, GSH synthesis or glutathione-
S-transferases (cited in Morrow, 1993 and Tew, 1994). Such a
hypothesis is in accordance with the recent report (Kuo et al, 1996)
showing, in human colorectal cancers, a frequent coordinated
overexpression of the MRP gene and the g-glutamylcysteine
synthetase (g-GCS) gene, an enzyme involved in GSH synthesis.
In conclusion, accurate andreliable quantitation ofdifferent types
ofMDR-related gene expression by fine and sensitive methods such
as RT-PCR presented in this paper, could provide a powerful tool to
easily investigate possible interrelationships between these genes on
a single tumour sample.The purpose of this methodological paper
was not to provide data on treatment outcome of patients, but the
clinical relevance of our data now needs to be investigated by
prospective clinical correlative studies, namely by sequential semi-
quantitative determination of different MDR-related gene expres-
sion in terms of prediction of response to chemotherapy, design of
studies aimed at reversal ofdrug resistance and also in terms ofthe
overall prognosis ofbreast carcinomas.
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